Mammoth Biosciences

Description

Develops in vivo gene-editing therapeutics, engineers CRISPR-Cas systems and editing strategies, and provides CRISPR-based detection technology for genetic medicine and molecular diagnostics.

Mammoth Biosciences is located in the Silicon Valley ecosystem.

Related

• Metagenomi ($MGX)Develops in vivo genome-editing systems derived from metagenomics to create genetic medicines intended to correct disease-causing mutations…
• Verve TherapeuticsSingle-course gene-editing therapies for cardiovascular disease. Cambridge MA; CRISPR-based PCSK9 + ANGPTL3 programs.
• Arbor BiotechnologiesDevelops gene editing treatments and genetic medicines using programmable DNA editors for people with genetic diseases, with a focus on CNS…
• Editas Medicine ($EDIT)Develops CRISPR-based gene editing medicines, including in vivo approaches, for people with serious diseases where modifying genes may…
• Genesis TherapeuticsBuilds molecular AI models and a design platform to optimize small-molecule drug discovery and create new medicines for partners and…
• InsitroBuilds AI systems using automated cellular experiments and population genetics to identify causal disease targets and design therapeutics…
• Scribe TherapeuticsEngineers CRISPR-based therapeutics by modifying natural CRISPR systems, with treatments focused on cardiometabolic disease and…
• Meridian BioscienceProvides life science products, molecular reagents, antibodies, antigens, blockers, services, and diagnostics platforms for laboratories…
• Colossal BiosciencesDevelops CRISPR-based genomics software tools and genetic engineering programs for de-extinction, including work on woolly mammoths using…
• ArsenalBioDevelops in vivo T cell therapies and reprogrammed CAR T approaches for chronic diseases, including cancer and autoimmunity, with focus on…
• CRISPR Therapeutics ($CRSP)CRISPR Therapeutics develops CRISPR-based gene-editing therapies across hemoglobinopathies, oncology, diabetes, and cardiovascular disease,…
• Umoja BiopharmaDevelops in vivo CAR T cell therapies and lentiviral manufacturing to support on-demand treatment, aiming to reduce ex vivo manufacturing…